ngµç×ÓÓÎϷҩѧԺÂÞº£±ò½ÌÊÚÑо¿ÍŶÓ×ÔÖ÷¿ªÕ¹Á˼ÓËÙµÄ×ÔÓÉÄÜ΢ÈÅ-¾ø¶ÔÁ¬Ïµ×ÔÓÉÄÜÅÌËãÐÂÒªÁ죨GA-FEP£©£¬£¬£¬È¡µÃÒ©ÎïÉè¼ÆÒªº¦ÊÖÒÕµÄÐÂÍ»ÆÆ£¬£¬£¬ÊµÏÖ×ÔÓÉÄÜ΢ÈÅ£¨FEP£©/Ò©ÎïÉè¼ÆÒªÁìµÄ¹ú²ú»¯ºÍ×ÔÖ÷¿É¿Ø¡£¡£ÔÚ¿¹»÷йڷÎÑ×Ñо¿ÖУ¬£¬£¬¸ÃGA-FEPÒªÁìÊ×´ÎÒ»ÖÜÄÚÍê³É¶ÔÀÏÒ©Êý¾Ý¿âµÄ¸ß¾«¶Èɸѡ£¬£¬£¬´Ó¶øÔ¤²â³ö25¸ö¶ÔйڷÎÑ×Ö÷ÂÑ°×øMproÓнϸßÇ×ЭÁ¦µÄÒ©Î£¬£¬½øÒ»²½µÄÌåÍâ»îÐÔÑéÖ¤·¢Ã÷ÁË15¸öM^proÒÖÖƼÁ£¨Ki Ϊ 0.04ÖÁ3.3 ?M£©£¬£¬£¬ÌåÏÖ³ö½Ï¸ßµÄ»îÐÔ»¯ºÏÎïÖÀÖÐÂÊ¡£¡£ÌØÊâÖµµÃÒ»ÌáµÄÊÇ£¬£¬£¬ÒÖÖÆ»îÐÔ×îÓŵÄÒ©ÎïË«à×´ïĪ¶ÔйڷÎÑ×»ñµÃ½ÏºÃµÄÁÙ´²ÖÎÁÆЧ¹û£¬£¬£¬´Ó¶ø½øÒ»²½ÑéÖ¤GA-FEPÒªÁìµÄ¿É¿¿ÐÔ¡£¡£¸ÃGA-FEPÒªÁì¼È¿ÉÒÔÏÔ×ÅÌá¸ßÒ©Îï/°Ð±êÇ×ЭÁ¦µÄÔ¤²â¾«¶È£¨ÀíÂÛÇ×ЭÁ¦ÓëʵÑéÇ×ЭÁ¦²îÖµ¾ø´ó´ó¶¼Ð¡ÓÚ2 kcal/mol£©£¬£¬£¬»¹¿ÉÒÔÌá¸ßÔ¤²âËÙÂÊ£¨¹Å°åFEPÒªÁìÿ¸ö»¯ºÏÎïµÄÔ¤²âʱ¼äΪ30-60Ì죬£¬£¬±¾ÒªÁìËõ¶ÌΪ1ÌìÒÔÄÚ£¬£¬£¬Ð§ÂÊÌá¸ß30-60±¶£©£¬£¬£¬´Ó¶øÌá¸ßÁ¢ÒìÒ©ÎïɸѡµÄÀÖ³ÉÂʲ¢½µµÍÑз¢Ê±¼ä¡£¡£³ýÁ˸߾«¶ÈɸѡÍ⣬£¬£¬¸ÃGA-FEPÒªÁ컹¿ÉÒÔÓ¦ÓÃÓÚÆäËûÐÂÒ©Éè¼ÆÊÂÇéÖУ¬£¬£¬Èç¹Ç¼ÜԾǨºÍÈ«ÐÂÒ©ÎïÉè¼ÆµÈ£¬£¬£¬ÒÔÌá¸ßÏȵ¼»¯ºÏÎïµÄ·¢Ã÷ºÍÓÅ»¯Ð§ÂÊ¡£¡£

ÉÏÊöÑо¿Ð§¹û£¬£¬£¬ÓÚ2020Äê10ÔÂ13ÈÕÒÔArticleÐÎʽ½ÒÏþÔÚPNAS£¬£¬£¬ÌâΪ"Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs"¡£¡£ngµç×ÓÓÎϷҩѧԺÀîÕܲ©Ê¿¡¢¡¢¡¢Öйúº£Ñó´óѧҽҩѧԺÀî꿲©Ê¿ÉúºÍngµç×ÓÓÎϷҩѧԺ»ÆÒÇÓв©Ê¿Îª±¾ÎĵIJ¢ÁеÚÒ»×÷Õß¡£¡£±¾ÎÄͨѶ×÷ÕßΪngµç×ÓÓÎϷҩѧԺÂÞº£±ò½ÌÊÚ¡¢¡¢¡¢Öйúº£Ñó´óѧҽҩѧԺÍõöνÌÊÚ¡¢¡¢¡¢¿ÏËþ»ù´óѧҩѧԺտ²ý¹ú½ÌÊÚºÍngµç×ÓÓÎÏ·ÉúÃü¿ÆѧѧԺ´ÞöÁ½ÌÊÚ¡£¡£ÖпÆÔºÉϺ£Ò©ÎïËù¡¢¡¢¡¢À¼ÖÝ´óѧ¡¢¡¢¡¢¹ãÖÝÒ½¿Æ´óѧµÈµ¥Î»Ò²¼ÓÈë±¾¿ÎÌâµÄÑо¿¡£¡£

±¾Ñо¿»ñµÃÁ˹ú¼ÒÖصãÑз¢ÍýÏë¡¢¡¢¡¢¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðÓÅÒìÇàÄê»ù½ðµÈ¾­·ÑµÄÖ§³Ö£¬£¬£¬Í¬Ê±Ò²»ñµÃÁËÌÚѶÔÆ£¬£¬£¬¹ãÖÝ¡¢¡¢¡¢ÉîÛÚ¡¢¡¢¡¢Ìì½ò¡¢¡¢¡¢±±¾©µÈ³¬µÈÅÌËãÖÐÐĵĴóÁ¦Ö§³Ö¡£¡£

Ñо¿Åä¾°£º

Ä¿½ñÈËÀ࿵½¡ÁìÓòÃæÁÙÈô¸ÉµÄÖØ´óÌôÕ½£¬£¬£¬°üÀ¨ÖØ´ó¼²²¡£¡£¨Èç¶ñÐÔÖ×Áö¡¢¡¢¡¢ÌÇÄò²¡¡¢¡¢¡¢ÐÄѪ¹Ü¼²²¡µÈ£©¼°Í»·¢µÄ¶ñÐÔѬȾ²¡£¡£¨ÈçйڷÎÑס¢¡¢¡¢SARS¡¢¡¢¡¢°£²©À­µÈ£©¡£¡£Òò´Ë£¬£¬£¬Ø½Ðè¼ÓËÙÐÂÒ©Ñз¢ËÙÂÊ£¬£¬£¬ÒÔÓ¦¶ÔÒÔÉÏÌôÕ½£¬£¬£¬ÓÈÆäÊÇ´ó¹æģͻ·¢ÒßÇéÀ´Ï®Ö®Ê±£¬£¬£¬¾¡¿ì»ñµÃÓ¦¼±Ò©ÎïÒÔ¿ØÖÆÒßÇéµÄ¿ªÕ¹¡£¡£ÔõÑù¾«×¼Ô¤²âÒ©ÎïÓë°Ð±êµÄÇ×ЭÁ¦£¨Á¬Ïµ×ÔÓÉÄÜ£©ÒÔ»ñµÃ¸ßÇ×ЭÁ¦µÄС·Ö×ÓÒ©Î£¬£¬Ò»Ö±ÊÇÅÌËã»ú¸¨ÖúÒ©ÎïÉè¼ÆÁìÓòµÄ¡°Ê¥±­¡±£¬£¬£¬ÈôÄܾ«×¼Ô¤²âÒ©Îï/°Ð±êÇ×ЭÁ¦£¬£¬£¬½«ÄܼÓËÙÏȵ¼»¯ºÏÎïÒ©ÎïµÄ·¢Ã÷¼°ÓÅ»¯Ð§ÂÊ£¬£¬£¬´Ó¶øÏÔ×ÅËõ¶ÌÐÂÒ©´´ÔìÖÜÆÚ¼°½µµÍÑз¢±¾Ç®¡£¡£

×ÔÓÉÄÜ΢ÈÅ£¨FEP£©ÊÇÒ»ÖÖ»ùÓÚͳ¼ÆÁ¦Ñ§ÀíÂÛÑÏ¿áÍƵ¼¶øÀ´µÄÒªÁ죬£¬£¬¾ßÓнϸߵÄÀíÂÛ¾«¶È£¬£¬£¬ÔÚÒ©Îï/°Ð±êÇ×ЭÁ¦Ô¤²â·½Ãæ¾ßÓкܺõÄÓ¦ÓÃÔ¶¾°¡£¡£È»¶ø£¬£¬£¬¸ÃÀàÒªÁì¶ÔÅÌËã×ÊÔ´ÏûºÄ¼«´ó£¨¹Å°åCPU·þÎñÆ÷ʹÓøÃÒªÁìÔ¤²âÒ»¸öÒ©ÎïÓë°Ð±êÇ×ЭÁ¦ÐèÒª1-2¸öÔ£©£¬£¬£¬ÇÒȱ·¦¹«ÈϵÄ×î¼ÑÁ÷³Ì£¬£¬£¬ÉÐδ»ñµÃÆÕ±éµÄÓ¦Óᣡ£½üÄ꣬£¬£¬Ò©ÎïÉè¼Æ¶¥¼¶Èí¼þѦ¶¨ÚÌ¿ªÕ¹µÄ×ÔÓÉÄÜ΢ÈÅ/Ïà¶Ô×ÔÓÉÄÜÔ¤²âÒªÁìÊܵ½ÖÆÒ©ºÍ¿ÆÑÐÊÂÇéÕߵļ«´ó¹Ø×¢£¨JACS 2015, 137, 2695£©£¬£¬£¬È»¶ø¸ÃÒªÁìÖ÷Òª±»Ó¦ÓÃÓÚÔ¤²â½á¹¹ÏàËÆÅäÌå¼äµÄÏà¶ÔÁ¬Ïµ×ÔÓÉÄÜ£¨Ò»°ãÁ½ÅäÌå½á¹¹²î±ðСÓÚ10¸öÖØÔ­×Ó£©£¬£¬£¬ÎÞ·¨Ô¤²â²î±ð¹Ç¼ÜµÄ»¯ºÏÎïÓë°Ð±êµÄÇ×ЭÁ¦£¬£¬£¬ÇÒÔÊÐíÓöÈÌڹ󣬣¬£¬ÏÞÖÆÁ˸ÃÒªÁìµÄÓ¦ÓùæÄ£¡£¡£

±¾´ÎÏ£Íû£º

1.¿ªÕ¹ÁË×ÔÓÉÄÜ΢ÈÅÐÂÒªÁìGA-FEP£¬£¬£¬È¡µÃÒ©ÎïÉè¼ÆÒªº¦ÊÖÒÕµÄÐÂÍ»ÆÆ£¬£¬£¬ÊµÏÖ×ÔÖ÷¿É¿Ø

ҩѧԺÂÞº£±ò/ÀîÕÜÑо¿ÍŶÓÒ»Ö±ÖÂÁ¦ÓÚ½«ÏÖ´úÎïÀíѧÊÖ¶ÎÓ¦ÓÃÓÚÐÂÒ©Ñз¢£¬£¬£¬ÒÔÌáÉýÒ©Îï/°Ð±êÇ×ЭÁ¦µÄÔ¤²â¾«¶È¼°ËÙÂÊ¡£¡£ÎªÁË¿ªÕ¹»ùÓÚFEPµÄÐÂÒªÁ죬£¬£¬²¢Íƶ¯¸ÃÒªÁìÕæÕýÓ¦ÓÃÓÚÐÂÒ©Éè¼Æ£¬£¬£¬¸ÃÏîÄ¿ÍŶӿªÕ¹ÁË»ùÓÚFEPµÄ¾ø¶ÔÁ¬Ïµ×ÔÓÉÄÜÅÌËãÒªÁ죨GA-FEP£©¡£¡£Ç°ÆÚÊÂÇéÖУ¬£¬£¬ËûÃÇͨ¹ýÑо¿FEPÅÌËã»ñµÃµÄ¸ÅÂÊÂþÑÜÌØÕ÷£¬£¬£¬Ñз¢Á˵ÚÒ»´úÓÃÓÚÔ¤²âÒ©Îï/°Ð±êÇ×ЭÁ¦£¨¾ø¶ÔÁ¬Ïµ×ÔÓÉÄÜ£©GA-FEPÒªÁ죬£¬£¬²¢Àֳɽ«¸ÃÒªÁìÓ¦ÓÃÓÚPDE10ÒÖÖƼÁÏȵ¼»¯ºÏÎïµÄÉè¼ÆºÍ½á¹¹ÓÅ»¯£¨´ÓÃçÍ·»¯ºÏÎïµ½Ïȵ¼»¯ºÏÎ£¬£¬ÒÖÖÆ»îÐÔ»ñµÃÁË2000¶à±¶µÄÌáÉý£¬£¬£¬J. Med. Chem. 2019, 62, 2099¨C2111£©¡£¡£

ΪÁË´ó·ù¶ÈÌá¸ßGA-FEPµÄÔ¤²âËÙÂÊ£¬£¬£¬ÒÔÌá¸ßÒ©ÎïÉè¼ÆЧÂÊ£¬£¬£¬ÏîÄ¿×éÍƵ¼ÁËÄÜ׼ȷÐÎòFEPÈÈÁ¦Ñ§Ñ­»·ÖÐÌí¼ÓÔ¼Êø·½·¨ ¸ÅÂÊÂþÑܵĹ«Ê½£¬£¬£¬²¢½«ÆäÃüÃûΪREDº¯Êý¡£¡£REDº¯Êý¼«´ó¼ÓËÙÁËGA-FEPÒªÁìµÄÔ¤²âËÙÂÊ¡£¡£Èçͼ1£¨a£©Ëùʾ£¬£¬£¬ÅÌËãÔ¼ÊøÄÜÁ¿Àú³ÌÖУ¬£¬£¬²ÉÑù»ñµÃµÄ £¨»Æµã£©¿ÉÒԺܺõر»REDº¯ÊýÄâºÏ£¨ºìÏߣ©¡£¡£Í¨³£À´½²£¬£¬£¬Ô¼ÊøÄÜÁ¿ÐèÒª12¸ö¦Ë´°Ì¸·æÆø¹»×¼È·ÅÌËã¡£¡£¶ø¾­REDº¯ÊýÆÊÎö£¬£¬£¬ÄâºÏ£¬£¬£¬²¢ÅÌËãÄÜÁ¿ºó£¬£¬£¬Ïà±ÈÓÚͨ³£µÄ12¸ö¦Ë´°¿Ú£¬£¬£¬ÐÂÒªÁìʹÓÃÒ»²½Î¢ÈÅ£¨2¸ö¦Ë´°¿Ú£©¼´¿É׼ȷÅÌËãÔ¼ÊøÄÜÁ¿¡£¡£Ê¹ÓÃ3¸ö°Ð±ê¼°28¸öÅäÌå¾ÙÐвâÊÔ£¬£¬£¬ÊÂÇéÖз¢Ã÷Ò»²½Î¢ÈÅ£¨2¦Ë´°¿Ú£©ÒÔ¼°12¦Ë´°¿ÚµÃ³öµÄЧ¹û»ù±¾Ò»Ö£¬£¬£¬¾ßÓм«ºÃµÄÏà¹ØÐÔ£¨ÈçÏÂͼËùʾ£©£¬£¬£¬¹ØÓÚËùÓÐϵͳ£¬£¬£¬Á½ÖÖ·½Ê½ÅÌËã»ñµÃµÄÎó²îСÓÚ0.5 kcal/mol¡£¡£ÕâЩÊÂÇéºÍ·¢Ã÷¼«´ó¼ÓËÙÁËFEP-ABFEµÄÔ¤²âËÙÂÊ£¬£¬£¬²¢Ê¹µÃGA-FEPÒªÁìÊ×´ÎÄÜÓ¦ÓÃÓÚÐÂÒ©µÄÐéÄâɸѡÑо¿ÖС£¡£

ͼ1. REDº¯ÊýÏÔ׿ÓËÙÔ¤²âËÙÂÊ

2.ʵÏÖGA-FEPÒªÁìÔÚÍ»·¢ÒßÇéÓ¦¼±Ò©ÎïÏìÓ¦·½ÃæµÄµä·¶Ó¦ÓÃ

йڲ¡¶¾·ÎÑ×´óÊ¢ÐÐÒѳÉΪȫÇòÐÔΣ»£»ú£¬£¬£¬µ«ÏÖÔÚÉÐȱÉÙÕë¶ÔйڷÎÑ×µÄÓÐÓÃÖÎÁÆÒªÁì¡£¡£Í¨¹ýÀÏÒ©ÐÂÓ㬣¬£¬ÓÐÍû¿ìËÙ·¢Ã÷½ÏΪÇå¾²µÄйڷÎÑ×ÖÎÁÆÒ©Îï¡£¡£ÍŶӽÓÄÉÁËÈçͼ2ËùʾµÄÑо¿Õ½ÂÔ£¬£¬£¬´ÓÒÑÖªÒ©ÎﻯºÏÎï¿â£¨º¬2500ÖÖÒ©ÎÖÐÑ°ÕÒÕë¶ÔйڷÎÑ×µÄÖÎÁÆÒ©Îï¡£¡£ÒÔйڲ¡¶¾SARS-CoV-2Ö÷ÂÑ°×ø£¨M^pro£©Îª°Ðµã£¬£¬£¬Ê×ÏȾ­Ì«¹ý×Ó¶Ô½Ó»ñµÃ100¸ö·Ö×Ó£¬£¬£¬´ËºóÒ»ÖÜÄÚÍê³ÉÁ×ÆÃ100¸ö»¯ºÏÎïÓëM^proµÄGA-FEPÔ¤²â£¬£¬£¬Ô¤²â³ö25¸öÀÏÒ©·Ö×Ó£¬£¬£¬ÌåÍâÉúÎïʵÑéÑéÖ¤15¸öÒ©Îï¶ÔM^pro¾ßÓнϸߵÄÒÖÖÆ»îÐÔ£¨Ki¾ùСÓÚ4 ¦ÌM£©£¬£¬£¬»îÐÔÒ©ÎïµÄÀÖ³ÉÂʸߴï60%¡£¡£ÌØÊâÖµµÃÒ»ÌáµÄÊÇ£¬£¬£¬Õâ16¸öÒ©ÎïÓë°Ð±êµÄÀíÂÛÇ×ЭÁ¦ÓëʵÑéÇ×ЭÁ¦²îÖµ¾ø´ó´ó¶¼¾ùСÓÚ2 kcal/mol£¬£¬£¬¶øÒ©ÎïÉè¼ÆÖг£ÓõÄMM-PBSAºÍGBSAÁ½ÖÖÒªÁì»ñµÃµÄ²îÖµ¾ù´óÓÚ10 kcal/mol£¬£¬£¬³ä·Ö˵Ã÷GA-FEPÒªÁìÔÚÒ©Îï/°Ð±êÇ×ЭÁ¦µÄÔ¤²â¾«¶È·½Ãæ¾ßÓÐÏÔ×ŵÄÓÅÊÆ¡£¡£×ܵÄÀ´Ëµ£¬£¬£¬GA-FEPÒªÁì²»µ«¿ÉÒÔÌá¸ßÒ©Îï/°Ð±êÇ×ЭÁ¦µÄÔ¤²â¾«¶È£¬£¬£¬»¹¿ÉÒÔÏÔ×ÅÌá¸ßÔ¤²âËÙÂÊ£¨¹Å°åFEPÒªÁìÿ¸ö»¯ºÏÎïµÄÔ¤²âÐèÒª30-60Ì죬£¬£¬±¾ÒªÁìËõ¶ÌΪ1ÌìÒÔÄÚ£¬£¬£¬Ð§ÂÊÌá¸ß30-60±¶£©£¬£¬£¬´Ó¶øÌá¸ßÁ¢ÒìÒ©ÎïɸѡµÄÀÖ³ÉÂʲ¢½µµÍÑз¢Ê±¼ä¡£¡£

ͼ2. ±¾Ñо¿½ÓÄÉ»ùÓÚGA-FEPµÄ¸ß¾«¶ÈɸѡսÂÔ

ÓÐÒâ˼µÄÊÇ£¬£¬£¬¿²µØɳ̹õ¥µÄ´úл²úÆ·¿²µØɳ̹Ҳ¶ÔM^pro¾ßÓнϺõÄÒÖÖÆ»îÐÔ¡£¡£DisulfiramºÍAtazanavirÔÚÆäËû±¨µÀÖÐÒ²±»È·Ö¤ÎªM^proÒÖÖƼÁ£¬£¬£¬ÆäÓà14¸ö¾ùÓɱ¾ÎÄÊ״η¢Ã÷ΪM^proÒÖÖƼÁ¡£¡£16¸öÒ©ÎïÖУ¬£¬£¬ÒÖÖÆ»îÐÔ×î¸ßµÄ»¯ºÏÎïΪÓɱ¾ÒªÁìÊ״η¢Ã÷µÄË«à×´ïĪ£¨Dipyridamole£¬£¬£¬Í¼3£©£¬£¬£¬KiΪ40 nM£¬£¬£¬½øÒ»²½²¡¶¾Ï¸°ûʵÑé»ñµÃ¸Ã»¯ºÏÎïµÄEC50 Ϊ100 nM¡£¡£ÌØÊâÖµµÃÒ»ÌáµÄÊÇ£¬£¬£¬ÔÚºóÐøÁ½ÂÖ¶àÖÐÐÄÁÙ´²ÊµÑéÖУ¬£¬£¬ÑéÖ¤Á˸û¯ºÏÎï¾ßÓнϺõÄÖÎÁÆЧ¹û£ºÔÚÁè¼Ý100ÀýµÄÁÙ´²ÊÔÑéÖУ¬£¬£¬Í¨Ë×ÐÍйڻ¼ÕßÈýÖܳöÔºÂÊΪ100%£¬£¬£¬ÖØÐÍ»¼ÕßÈýÖܳöÔºÂÊΪ87.5%¡£¡£²¿·ÖÁÙ´²Ð§¹ûÒѽÒÏþÔÚҩѧȨÍþÆÚ¿¯Acta Pharm. Sin. B£¨2020, 10, 1205-1215£©£¬£¬£¬²¢ÈëÑ¡½ñÄê7Ô·ݸÿ¯µÄ·âÃæ¹ÊÊ¡£¡£

ͼ3. ͨ¹ý×ÔÓÉÄÜ΢ÈÅGA-FEPÒªÁì¸ß¾«¶Èɸѡ»ñµÃ2¸ö»îÐÔ×îÓŵÄM^proÒÖÖƼÁ

ÂÛÎÄÁ´½Ó£ºhttps://doi.org/10.1073/pnas.2010470117